POZN

UPDATE 2-Pozen pain drug meets main goal in late-stage trial - 12/03 - 01:06 PM ET

Pozen reports positive results on arthritis medicine - 12/03 - 01:02 PM ET

UPDATE 1-Pozen pain drug meets main goal in late-stage trial - 12/03 - 10:34 AM ET

BRIEF-POZEN announces positive top line results for its PN 400 phase 3 trials - 12/03 - 08:12 AM ET

POZEN Announces Positive Top Line Results for Its PN 400 Phase 3 Trials - 12/03 - 08:00 AM ET

POZEN'S PA32520 Study Data Demonstrated Better Upper Gastrointestinal Protection - 11/11 - 11:00 AM ET

Slow Treximet launch hurts Pozen - 10/30 - 05:45 AM ET

Pozen Narrows Guidance Below Estimates - 10/29 - 07:55 AM ET

POZEN INC REUTERS ESTIMATES FY 2008 REV VIEW $63.49 MLN - 10/29 - 07:41 AM ET

POZEN INC REUTERS ESTIMATES Q3 SHR VIEW $-0.21, REV VIEW $10.28 MLN - 10/29 - 07:40 AM ET

POZEN INC Q3 REVENUE $11.1 MLN VS $27.6 MLN - 10/29 - 07:32 AM ET

POZEN INC Q3 SHR LOSS $0.26 - 10/29 - 07:32 AM ET

POZEN INC SEES FY 2008 REVENUE $62 MLN TO $64 MLN - 10/29 - 07:32 AM ET

POZEN Reports Third Quarter 2008 Results - 10/29 - 07:30 AM ET

RBC CUTS POZEN INC PRICE TARGET TO $11 FROM $15; RATING OUTPERFORM - 10/24 - 08:00 AM ET

POZEN Announces October 29, 2008 Webcast of Third Quarter 2008 Results - 10/22 - 09:31 AM ET

Copernicus Group IRB Announces New Incoming CEO - 10/22 - 08:11 AM ET

JEFFERIES CUTS POZEN INC TO UNDERPERFORM FROM HOLD - 10/20 - 07:04 AM ET

BRIEF: Bad news pushes Pozen shares down - 10/18 - 05:39 AM ET

POZEN Finishes At Lowest Level Since July 2006 - 10/17 - 04:18 PM ET

Page 1 of 5     1  2   3   4   5      Previous  |  Next

<< Back to Stock Index